Treatment of cutaneous lymphomas: Today and tomorrow

Actas Dermo-Sifiliograficas

Volumn 100, Issue SUPPL. 1, 2009, Pages 18-32

  Mestel, D S ^a   Beyer, M ^a   Steinhoff, M ^a   Sterry, W ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

Chemotherapy; Conventional therapy; Emerging drugs; HDACI; Monoclonal antibody; Primary cutaneous lymphoma

Indexed keywords

ALEMTUZUMAB; ALPHA INTERFERON; ANTIHISTAMINIC AGENT; ANTILIPEMIC AGENT; BEXAROTENE; BORTEZOMIB; CARMUSTINE; CHLORAMBUCIL; CHLORMETHINE; CORTICOSTEROID; CYCLOPHOSPHAMIDE; DENILEUKIN DIFTITOX; DOXORUBICIN; FORODESINE; GEMCITABINE; HISTONE DEACETYLASE INHIBITOR; HYBRID PROTEIN; INTERFERON; LEVOTHYROXINE; METHOTREXATE; MONOCLONAL ANTIBODY; PARACETAMOL; PREDNISONE; PROTEASOME INHIBITOR; PSORALEN; RETINOID; UNINDEXED DRUG; VINCRISTINE; VORINOSTAT; ZANOLIMUMAB;

ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ANEMIA; B CELL LYMPHOMA; BACKACHE; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURVIVAL; CAPILLARY LEAK SYNDROME; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; COLD SENSATION; CUTANEOUS T CELL LYMPHOMA; DERMATITIS; DIARRHEA; DRUG ACTIVITY; DRUG BLOOD LEVEL; DRUG CONCENTRATION; DRUG EFFICACY; DRUG ERUPTION; DRUG HALF LIFE; DRUG RESPONSE; DRUG TOLERABILITY; DRUG TOLERANCE; DYSGEUSIA; DYSPNEA; ECZEMA; EDEMA; FATIGUE; GASTROINTESTINAL TOXICITY; HEART VENTRICLE TACHYCARDIA; HEMOLYTIC UREMIC SYNDROME; HUMAN; HYPERLIPIDEMIA; HYPOTHYROIDISM; LABORATORY TEST; LEUKOPENIA; LOW DRUG DOSE; LYMPHOCYTOPENIA; MULTIPLE CYCLE TREATMENT; MYCOSIS FUNGOIDES; NAUSEA; NEUTROPENIA; OVERALL SURVIVAL; PHOTOTHERAPY; PNEUMONIA; PRIMARY TUMOR; PROGNOSIS; PRURITUS; PUVA; REVIEW; SEZARY SYNDROME; SIDE EFFECT; SKIN LYMPHOMA; THORAX PAIN; THROMBOCYTOPENIA; TOTAL SKIN ELECTRON THERAPY; TRIACYLGLYCEROL BLOOD LEVEL; ULTRAVIOLET B RADIATION; UPPER RESPIRATORY TRACT INFECTION;

EID: 75449092713     PISSN: 00017310     EISSN: 15782190     Source Type: Journal    
DOI: 10.1016/S0001-7310(09)73165-5     Document Type: Article

References (131)

1. E. Diamandidou, M. Colome-Grimmer, L. Fayad, M. Duvic, and R. Kurzrock Transformation of mycosis fungoides/Sézary syndrome: clinical characteristics and prognosis Blood 92 1998 1150 1159 (Pubitemid 28369027)
2. R.S. Siegel, T. Pandolfino, J. Guitart, S. Rosen, and T.M. Kuzel Primary cutaneous T-cell lymphoma: review and current concepts J Clin Oncol 18 2000 2908 2925 (Pubitemid 30620080)
3. M. Girardi, P.W. Heald, and L.D. Wilson The pathogenesis of mycosis fungoides N Engl J Med 350 2004 1978 1988 (Pubitemid 38580201)
4. M. Paulli, and E. Berti Cutaneous T-cell lymphomas (including rare subtypes). Current concepts. II Haematologica 89 2004 1372 1388 (Pubitemid 39540575)
5. R. Willemze, and R.C. Beljaards Spectrum of primary cutaneous CD30 (Ki-1)-positive lymphoproliferative disorders. A proposal for classification and guidelines for management and treatment J Am Acad Dermatol 28 1993 973 980 (Pubitemid 23160651)
6. R. Willemze, E.S. Jaffe, G. Burg, L. Cerroni, E. Berti, and S.H. Swerdlow WHO-EORTC classification for cutaneous lymphomas Blood 105 2005 3768 3785 (Pubitemid 40656118)
7. E. Olsen, E. Vonderheid, N. Pimpinelli, R. Willemze, Y. Kim, and R. Knobler Revisions to the staging and classification of mycosis fungoides and Sézary syndrome: a proposal of the International Society for Cutaneous Lymphomas (ISCL) and the Cutaneous Lymphoma Task Force of the European Organization of Research and Treatment of Cancer (EORTC) Blood 110 2007 1713 1722 (Pubitemid 47443880)
8. V.D. Criscione, and M.A. Weinstock Incidence of cutaneous T-cell lymphoma in the United States, 1973-2002 Arch Dermatol 143 2007 854 895
9. Y.H. Kim, R.A. Jensen, G.L. Watanabe, A. Varghese, and R.T. Hoppe Clinical stage IA (limited patch and plaque) mycosis fungoides. A long-term outcome analysis Arch Dermatol 132 1996 1309 1313 (Pubitemid 26386618)
10. H.L. Liu, R.T. Hoppe, S. Kohler, J.D. Harvell, S. Reddy, and Y.H. Kim CD30+ cutaneous lymphoproliferative disorders: the Stanford experience in lymphomatoid papulosis and primary cutaneous anaplastic large cell lymphoma J Am Acad Dermatol 49 2003 1049 1058 (Pubitemid 37475476)
11. L. Cerroni, S. Signoretti, G. Höfler, G. Annessi, B. Pütz, and E. Lackinger Primary cutaneous marginal zone B-cell lymphoma: a recently described entity of low-grade malignant cutaneous B-cell lymphoma Am J Surg Pathol 21 1997 1307 1315 (Pubitemid 27460857)
12. J.J. Hoefnagel, M.H. Vermeer, P.M. Jansen, G.J. Fleuren, C.J. Meijer, and R. Willemze Bcl-2, Bcl-6 and CD10 expression in cutaneous B-cell lymphoma: further support for a follicle centre cell origin and differential diagnostic significance Br J Dermatol 149 2003 1183 1191 (Pubitemid 38058094)
13. F.J. Kaye, P.A. Bunn Jr, S.M. Steinberg, J.L. Stocker, D.C. Ihde, A.B. Fischmann, et al. A randomized trial comparing combination electron-beam radiation and chemotherapy with topical therapy in the initial treatment of mycosis fungoides N Engl J Med 321 1998 1784 1790
14. K.J. Neelis, E.C. Schimmel, M.H. Vermeer, N.J. Senff, R. Willemze, and E.M. Noordijk Low-dose palliative radiotherapy for cutaneous B- and T-cell lymphomas Int J Radiat Oncol Biol Phys 74 2009 154 158
15. F. Trautinger, R. Knobler, R. Willemze, K. Peris, R. Stadler, L. Laroche, et al. EORTC consensus recommendations for the treatment of mycosis fungoides/Sézary syndrome Eur J Cancer 42 2006 1014 1030
16. H.S. Zackheim, M. Kashani-Sabet, and S. Amin Topical corticosteroids for mycosis fungoides. Experience in 79 patients Arch Dermatol 134 1998 949 954 (Pubitemid 28385316)
17. E.J. Kim, S. Hess, S.K. Richardson, S. Newton, L.C. Showe, and B.M. Benoit Immunopathogenesis and therapy of cutaneous T cell lymphoma J Clin Invest 115 2005 798 812 (Pubitemid 40489380)
18. D.L. Ramsay, P.S. Halperin, and A. Zeleniuch-Jacquotte Topical mechlorethamine therapy for early stage mycosis fungoides J Am Acad Dermatol 19 1988 684 691 (Pubitemid 18239617)
19. Y.H. Kim, G. Martínez, A. Varghese, and R.T. Hoppe Topical nitrogen mustard in the management of mycosis fungoides: update of the Stanford experience Arch Dermatol 139 2003 165 173 (Pubitemid 36216254)
20. H.S. Zackheim Topical carmustine (BCNU) in the treatment of mycosis fungoides Dermatol Ther 16 2003 299 302 (Pubitemid 38044673)
21. S.J. Whittaker, J.R. Marsden, M. Spittle, and R. Russell Jones Joint British Association of Dermatologists and and UK Cutaneous Lymphoma Group guidelines for the management of primary cutaneous T-cell lymphomas Br J Dermatol 149 2003 1095 1107 (Pubitemid 38058085)
22. D.L. Ramsay, K.M. Lish, C.B. Yalowitz, and N.A. Soter Ultraviolet-B phototherapy for early-stage cutaneous T-cell lymphoma Arch Dermatol 128 1992 931 933
23. P.V. Diederen, H. van Weelden, C.J. Sanders, J. Toonstra, and W.A. van Vloten Narrowband UVB and psoralen-UVA in the treatment of early-stage mycosis fungoides: a retroperspective study J Am Acad Dermatol 48 2003 215 219 (Pubitemid 36232319)
24. C. Querfeld, S.T. Rosen, T.M. Kuzel, K.A. Kirby, H.H. Roenigk Jr, and B.M. Prinz Long-term follow-up of patients with early-stage cutaneous T-cell lymphoma who achieved complete remission with psoralen plus UV-A monotherapy Arch Dermatol 141 2005 305 311 (Pubitemid 40365446)
25. E.A. Abel, E. Sendagorta, R.T. Hoppe, and C.H. Hu PUVA treatment of erythrodermic and plaque-type mycosis fungoides. Ten-year follow-up study Arch Dermatol 123 1987 897 901 (Pubitemid 17090478)
26. F.J. Child, T.J. Mitchell, S.J. Whittaker, J.J. Scarisbrick, P.T. Seed, and R. Russell-Jones A randomized cross-over study to compare PUVA and extracorporeal photopheresis in the treatment of plaque stage (T2) mycosis fungoides Clin Exp Dermatol 29 2004 231 236 (Pubitemid 38658459)
27. J.J. Scarisbrick, P. Taylor, U. Holtick, Y. Makar, K. Douglas, G. Berlin, et al. U.K. consensus statement on the use of extracorporeal photopheresis for treatment of cutaneous T-cell lymphoma and chronic graft-versus-host disease Br J Dermatol 158 2008 659 678
28. K.E. McKenna, S. Whittaker, L.E. Rhodes, P. Taylor, J. Lloyd, and S. Ibbotson Evidence-based practice of photopheresis 1987-2001: a report of a workshop of the British Photodermatology Group and the U.K. Skin Lymphoma Group Br J Dermatol 154 2006 7 20 (Pubitemid 43381314)
29. R. Edelson, C. Berger, F. Gasparro, B. Jegasothy, P. Heald, and B. Wintroub Treatment of cutaneous T-cell lymphoma by extracorporeal photochemotherapy. Preliminary results N Engl J Med 316 1987 297 303 (Pubitemid 17036377)
30. R. Knobler, and C. Jantschitsch Extracorporeal photoimmunochemotherapy in cutaneous T-cell lymphoma Transfus Apheresis Sci 28 2003 81 89 (Pubitemid 36298594)
31. B.D. Smith, and L.D. Wilson Management of mycosis fungoides. Treatment: part 2 Oncology 17 2003 1419 1428
32. G.W. Jones, B.M. Kacinski, L.D. Wilson, R. Willemze, M. Spittle, G. Hohenberg, et al. Total skin electron radiation in the management of mycosis fungoides: Consensus of the European Organization for Research and Treatment of Cancer (EORTC) Cutaneous Lymphoma Project Group J Am Acad Dermatol 47 2002 364 370
33. G.W. Cotter, R.J. Baglan, T.H. Wasserman, and W. Mill Palliative radiation treatment of cutaneous mycosis fungoides-a dose response Int J Radiat Oncol Biol Phys 9 1983 1477 1480 (Pubitemid 14227129)
34. E.A. Olsen, and P.A. Bunn Interferon in the treatment of cutaneous T-cell lymphoma Hematol Oncol Clin North Am 9 1995 1089 1107
35. O. Jumbou, J.M. N'guyen, M.H. Tessier, B. Legoux, and B. Dréno Long-term follow-up in 51 patients with mycosis fungoides and Sezary syndrome treated by interferon-alfa Br J Dermatol 140 1999 427 431 (Pubitemid 29182872)
36. E.A. Olsen Interferon in the treatment of cutaneous T-cell lymphoma Dermatol Ther 16 2003 311 321 (Pubitemid 38044675)
37. R. Stadler, H.G. Otte, T. Luger, B.M. Henz, P. Kühl, and T. Zwingers Prospective randomized multicenter clinical trial on the use of interferon-2a plus acitretin versus interferon-2a plus PUVA in patients with cutaneous T-cell lymphoma stages I and II Blood 92 1998 3578 3581 (Pubitemid 28525182)
38. C. Zhang, P. Hazarika, X. Ni, D.A. Weidner, and M. Duvic Induction of apoptosis by bexarotene in cutaneous T-cell lymphoma cells: relevance to mechanism of therapeutic action Clin Cancer Res 8 2002 1234 1240 (Pubitemid 34517663)
39. M.F. Boehm, L. Zhang, B.A. Badea, S.K. White, D.E. Mais, and E. Berger Synthesis and structure-activity relationships of novel retinoid X receptor-selective retinoids J Med Chem 37 1994 2930 2941 (Pubitemid 24297810)
40. M. Duvic, A.G. Martin, Y. Kim, E. Olsen, G.S. Wood, C.A. Crowley Worldwide Bexarotene Study Group Phase 2 and 3 clinical trial of oral bexarotene (Targretin capsules) for the treatment of refractory or persistent early-stage cutaneous T-cell lymphoma Arch Dermatol 137 2001 581 593 (Pubitemid 32458440)
41. M. Duvic, K. Hymes, P. Heald, D. Breneman, A.G. Martin, P. Myskowski Bexarotene Worldwide Study Group Bexarotene is effective and safe for treatment of refractory advanced-stage cutaneous T-cell lymphoma: multinational phase II-III trial results J Clin Oncol 19 2001 2456 2471 (Pubitemid 32391217)
42. C. Assaf, M. Bagot, R. Dummer, M. Duvic, R. Gniadecki, and R. Knobler Minimizing adverse side-effects of oral bexarotene in cutaneous T-cell lymphoma: an expert opinion Br J Dermatol 155 2006 261 266 (Pubitemid 44050557)
43. F. Foss Clinical experience with denileukin diftitox (ONTAK) Semin Oncol 33 2006 21 25
44. R.J. Kreitman Recombinant toxins for the treatment of cancer Curr Opin Mol Ther 5 2003 44 51
45. E. Olsen, M. Duvic, A. Frankel, Y. Kim, A. Martin, and E. Vonderheid Pivotal phase III trial of two dose levels of denileukin diftitox for the treatment of cutaneous T-cell lymphoma J Clin Oncol 19 2001 376 388 (Pubitemid 32112849)
46. A. Negro-Vilar, Z. Dziewanowska, E.S. Groves, V. Stevens, J.K. Zhang, M. Prince, et al. Efficacy and safety of denileukin diftitox (Dd) in a phase III, double-blind, placebo-controlled study of CD25+ patients with cutaneous T-cell lymphoma (CTCL) J Clin Oncol 25 Suppl 2007 8026
47. D. Greiner, E.A. Olsen, and G. Petroni Pentostatin (2'-deoxycoformycin) in the treatment of cutaneous T-cell lymphoma J Am Acad Dermatol 36 1997 950 955 (Pubitemid 27265908)
48. E.A. Coors, and P. von den Driesch Treatment of erythrodermic cutaneous T-cell lymphoma with intermittent chlorambucil and fluocortolone therapy Br J Dermatol 143 2000 127 131
49. G. Akpek, H.K. Koh, S. Bogen, C. O'Hara, and F.M. Foss Chemotherapy with etoposide, vincristine, doxorubicin, bolus cyclophosphamide, and oral prednisone in patients with refractory cutaneous T-cell lymphoma Cancer 86 1999 1368 1376 (Pubitemid 29447025)
50. A.A. Gabizon Selective tumor localization and improved therapeutic index of anthracyclines encapsulated in long-circulating liposomes Cancer Res 52 1992 891 896
51. U. Wollina, R. Dummer, N.H. Brockmeyer, H. Konrad, J.O. Busch, and M. Kaatz Multicenter study of pegylated liposomal doxorubicin in patients with cutaneous T-cell lymphoma Cancer 98 2003 993 1001 (Pubitemid 37022100)
52. S. Pulini, S. Rupoli, G. Goteri, N. Pimpinelli, R. Alterini, and A. Tassetti Pegylated liposomal doxorubicin in the treatment of primary cutaneous T-cell lymphomas Haematologica 92 2007 686 689 (Pubitemid 350144273)
53. C. Dumontet, F. Morschhauser, P. Solal-Celigny, F. Bouafia, E. Bourgeois, and C. Thieblemont Gemcitabine as a single agent in the treatment of relapsed or refractory low-grade non-Hogkin's lymphoma Br J Haematol 113 2001 772 778 (Pubitemid 32524402)
54. E. Marchi, L. Alinari, M. Tani, V. Stefoni, N. Pimpinelli, and E. Berti Gemcitabine as frontline treatment for cutaneous T-cell lymphoma: phase II study of 32 patients Cancer 104 2005 2437 2441 (Pubitemid 41691565)
55. I.S. Kazmers, B.S. Mitchell, P.E. DaDonna, L.L. Wotring, L.B. Townsend, and W.N. Kelley Inhibition of purine nucleoside phosphorylase by 8-aminoguanosin: selective toxicity for T-lymphocytes Science 214 1981 1137 1139
56. S. Bantia, P.J. Miller, C.D. Parker, S.L. Ananth, L.L. Horn, and J.M. Kilpatrick Purine nucleoside phosphorylase inhibitor BCX-1777 (Immucillin-H) - a novel potent and orally active immunosuppressive agent Int Immunopharmacol 1 2001 1199 1210 (Pubitemid 32434435)
57. S. Bantia, S.L. Ananth, C.D. Parker, L.L. Horn, and R. Upshaw Mechanism of inhibition of T-acute lymphoblastic leukemia cells by PNP inhibitor-BCX-1777 Int Immunopharmacol 3 2003 879 887 (Pubitemid 36629453)
58. M. Duvic, A. Forero-Torres, F. Foss, E. Olsen, and Y. Kim Response to oral forodesine in refractory cutaneous T-cell lymphoma: interim results of a phase I/II study Blood 110 Suppl 2006 22
59. A. Korycka, J.Z. Blonski, and T. Robak Forodesine (BCX-1777, Immucillin H) - a new purine nucleoside analogue: mechanism of action and potential clinical application Mini Rev Med Chem 7 2007 976 983 (Pubitemid 47554785)
60. L.S. Villadsen, L. Skov, T.N. Dam, F. Dagnaes-Hansen, J. Rygaard, and J. Schuurman In situ depletion of CD4(+) T cells in human skin by Zanolimumab Arch Dermatol Res 298 2007 449 455 (Pubitemid 46144206)
61. S. Marschner, T. Hunig, J.C. Cambier, and T.H. Finkel Ligation of human CD4 interferes with antigen-induced activation of primary T-cells Immunol Lett 82 2002 131 139 (Pubitemid 34468044)
62. Y.H. Kim, M. Duvic, E. Obitz, R. Gniadecki, L. Iversen, and A. Osterborg Clinical efficacy of zanolimumab (HuMax-CD4): two phase 2 studies in refractory cutaneous T-cell lymphoma Blood 109 2007 4655 4662 (Pubitemid 46827755)
63. C. Assaf, and W. Sterry Drug evaluation: zanolimumab, a human monoclonal antibody targeted against CD4 Curr Opin Mol Ther 9 2007 197 203 (Pubitemid 46623953)
64. M. Duvic, Y. Kim, N.J. Korman, B. Boh, A. Lerner, M.P. Heffernan, et al. Zanolimumab, a fully human monoclonal antibody: Early results of an ongoing clinical trial in patients with CD4+ mycosis fungoides (MF) type CTCL (stage IB-IVB) who are refractory or intolerant to targretin and one other standard therapy Blood 108 Suppl 2006 2731
65. D.S. Mestel, M. Beyer, M. Möbs, M. Steinhoff, W. Sterry, and C. Assaf Zanolimumab, a human monoclonal antibody targeting CD4 in the treatment of mycosis fungoides and Sézary syndrome Expert Opin Biol Ther 8 2008 1929 1939
66. C.E. Dearden, E. Matutes, and D. Catovsky Alemtuzumab in T-cell malignancies Med Oncol 19 2002 27 32
67. W. Rowan, J. Tite, P. Topley, and S.J. Brett Cross-linking of the CAMPATH-1 antigen (CD-52) mediates growth inhibition in human B- and T-lymphoma cell lines, and subsequent emergence of CD52-deficient cells Immunology 95 1998 427 436 (Pubitemid 28505700)
68. J. Lundin, A. Osterborg, G. Brittinger, D. Crowther, H. Dombret, A. Engert, et al. CAMPATH-1H monoclonal antibody in therapy for previously treated low-grade non-Hodgkin's lymphomas: a phase II multicenter study. European Study Group of CAMPATH-1H Treatment in Low-Grade Non-Hodgkin's Lymphoma J Clin Oncol 16 1998 3257 3263
69. J. Lundin, H. Hagberg, J.R. Repp, E. Cavallin-Stahl, S. Fredén, and G. Juliusson Phase II Study of Alemtuzumab (anti-CD52 monoclonal antibody) in patients with advanced mycosis fungoides/Sézary syndrome Blood 101 2003 4267 4272 (Pubitemid 36857787)
70. M.G. Bernengo, P. Quaglino, A. Comessatti, M. Ortoncelli, M. Novelli, and F. Lisa Low-dose intermittent alemtuzumab in the treatment of Sézary syndrome: clinical and immunologic findings in 14 patients Haematologica 92 2007 784 794 (Pubitemid 350155304)
71. G.A. Kennedy, J.F. Seymour, M. Wolf, H. Januszewicz, J. Davison, and C. McCormack Treatment of patients with advanced mycosis fungoides and Sézary syndrome with alemtuzumab Eur J Haematol 71 2003 250 256 (Pubitemid 37174695)
72. D.J. Lenihan, A.J. Alencar, D. Yang, R. Kurzrock, M.J. Keating, and M. Duvic Cardiac toxicity of alemtuzumab in patients with mycosis fungoides/Sézary syndrome Blood 104 2004 655 658 (Pubitemid 38970557)
73. J. Lundin, B. Kennedy, C. Dearden, M.J. Dyer, and A. Osterborg No cardiac toxicity associated with alemtuzumab therapy for mycosis fungoides/ Sézary syndrome Blood 105 2005 4148 4149 (Pubitemid 40656170)
74. J.E. Bolden, M.J. Peart, and R.W. Johnstone Anticancer activities of histone deacetylase inhibitors Nat Rev Drug Discov 5 2006 769 784 (Pubitemid 44348499)
75. S. Timmermann, H. Lehrmann, A. Polesskaya, and A. Harel-Bellan Histone acetylation and disease Cell Mol Life Sci 58 2001 728 736 (Pubitemid 32553030)
76. W.K. Rasheed, R.W. Johnstone, and H.M. Prince Histone deacetylase inhibitors in cancer therapy Expert Opin Investig Drugs 16 2007 659 678 (Pubitemid 46729100)
77. D. Marchion, and P. Münster Development of histone deacetylase inhibitors for cancer treatment Expert Rev Anticancer Ther 7 2007 583 598 (Pubitemid 46690964)
78. J.L. Marshall, N. Rizvi, J. Kauh, W. Dahut, M. Figuera, and M.H. Kang A phase I trial of depsipeptide (FR901228) in patients with advanced cancer J Exp Ther Oncol 2 2002 325 332 (Pubitemid 35265981)
79. E.L. Strevel, D.J. Ing, and L.L. Siu Molecularly targeted oncology therapeutics and prolongation of the QT interval J Clin Oncol 25 2007 3362 3371 (Pubitemid 47325624)
80. W.K. Kelly, O.A. O'Connor, L.M. Krug, J.H. Chiao, M. Heaney, and T. Curley Phase I study of an oral histone deacetylase inhibitor, suberoylanilide hydroxamic acid, in patients with advanced cancer J Clin Oncol 23 2005 3923 3931 (Pubitemid 46218695)
81. L.M. Butler, D.B. Agus, H.I. Scher, B. Higgins, A. Rose, and C. Cordon-Cardo Suberoylanilide hydroxamic acid, an inhibitor of histone deacetylase, suppresses the growth of prostate cancer cells in vitro and in vivo Cancer Res 60 2000 5165 5170 (Pubitemid 30739775)
82. S. Sakajiri, T. Kumagai, N. Kawamata, T. Saitoh, J.W. Said, and H.P. Koeffler Histone deacetylase inhibitors profoundly decrease proliferation of human lymphoid cancer cell lines Exp Hematol 33 2005 53 61 (Pubitemid 40127644)
83. C. Zhang, V. Richon, X. Ni, T. Saitoh, J.W. Said, and H.P. Koeffler Selective induction of apoptosis by histone deacetylase inhibitor SAHA in cutaneous T-cell lymphoma cells: relevance to mechanism of therapeutic action J Invest Dermatol 125 2005 1045 1052
84. E.A. Olsen, Y.H. Kim, T.M. Kuzel, T.R. Pacheco, F.M. Foss, and S. Parker Phase IIb multicenter trial of vorinostat in patients with persistent, progressive, or treatment refractory cutaneous T-cell lymphoma J Clin Oncol 25 2007 3109 3115 (Pubitemid 47218059)
85. M. Duvic, R. Talpur, X. Ni, C. Zhang, P. Hazarika, and C. Kelly Phase 2 trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) for refractory cutaneous T-cell lymphoma (CTCL) Blood 109 2007 31 39 (Pubitemid 46053039)
86. P.A. Konstantinopoulos, G.P. Vandoros, and A.G. Papavassiliou FK228 (depsipeptide): a HDAC inhibitor with pleiotropic antitumor activities Cancer Chemother Pharmacol 58 2006 711 715
87. P.A. Bunn Jr, and F.M. Foss T-cell lymphoma cell lines (HUT102 and HUT78) established at the National Cancer Institute: history and importance to understanding the biology, clinical features, and therapy of cutaneous T-cell lymphomas (CTCL) and adult T-cell leukemia-lymphomas (ATLL) J Cell Biochem Suppl 24 1996 12 23 (Pubitemid 26277218)
88. R.L. Piekarz, R. Robey, V. Sandor, S. Bakke, W.H. Wilson, L. Dahmoush, et al. Inhibitor of histone deacetylation, depsipeptide (FR901228), in the treatment of peripheral and cutaneous T-cell lymphoma: a case report Blood 98 2001 2865 2868
89. R. Piekarz, R. Frye, J. Wright, W. Figg, S. Allen, M. Kirschbaum, et al. Update of the NCI multiinstitutional phase II trial of romidepsin, FK228, for patients with cutaneous or peripheral T-cell lymphoma J Clin Oncol 25 Suppl 2007 8027
90. M. Prince, D. George, R. Johnstone, C. McCormack, L. Ellis, R. Williams-Truax, et al. LBH589, a novel deacetylase inhibitor (DACi), treatment of patients with cutaneous T-cell lymphoma (CTCL). Skin expression profiles in the first 24 h related to clinical response following therapy Blood 108 Suppl 2006 2715
91. T. Fisher, A. Patnaik, K. Bhalla, J. Beck, J. Morganroth, G.H. Laird, et al. Results of cardiac monitoring during phase I trials of a novel histone deacetylase inhibitor LBH589 in patients with advanced solid tumors and hematologic malignancies J Clin Oncol 23 Suppl 2005 3106
92. L. Zhang, D. Lebwohl, E. Masson, G. Laird, M.R. Cooper, and H.M. Prince Clinically relevant QTc prolongation is not associated with current dose schedules of LBH589 (panobinostat) J Clin Oncol 26 2008 332 333
93. R. Advani, K. Hymes, B. Pohlman, E. Jacobsen, J. McDonnell, R. Belt, et al. Belinostat (PXD101) in patients with recurrent or refractory peripheral or cutaneous T-cell lymphoma: results of a phase II study Blood 110 Suppl 2007 3453
94. D. Chauhan, T. Hideshima, C. Mitsiades, P. Richardson, and K.C. Anderson Proteasome inhibitor therapy in multiple myeloma Mol Cancer Ther 4 2005 686 692 (Pubitemid 40601851)
95. A. Sors, F. Jean-Louis, E. Bégué, L. Parmentier, L. Dubertret, and M. Dreano Inhibition of I{kappa}B Kinase subunit 2 in cutaneous T-cell lymphoma down-regulates nuclear factor-{kappa}B constitutive activation, induces cell death, and potentiates the apoptotic response to antineoplastic chemotherapeutic agents Clin Cancer Res 14 2008 901 911 (Pubitemid 351231175)
96. P.L. Zinzani, G. Musuraca, M. Tani, V. Stefoni, E. Marchi, and M. Fina Phase II trial of proteasome inhibitor bortezomib in patients with relapsed or refractory cutaneous T-cell lymphoma J Clin Oncol 25 2007 4293 4297 (Pubitemid 47548570)
97. D.A. Pichardo, C. Querfeld, J. Guitart, T.M. Kuzel, and S.T. Rosen Cutaneous T-cell lymphoma: a paradigm for biological therapies Leuk Lymphoma 45 2004 1755 1765 (Pubitemid 38997141)
98. R.F. Duarte, N. Schmitz, O. Servitje, and A. Sureda Haematopoietic stem cell transplantation for patients with primary cutaneous T-cell lymphoma Bone Marrow Transplant 41 2008 597 604
99. R.K. Burt, J. Guitart, A. Traynor, C. Link, S. Rosen, and T. Pandolfino Allogeneic hematopoietic stem cell transplantation for advanced mycosis fungoides: evidence of a graftversus-tumor effect Bone Marrow Transplant 25 2000 111 113 (Pubitemid 30093166)
100. M.C. Koeppel, A.M. Stoppa, M. Resbeut, D. Blaise, M. Coignet, and L. Coulier Mycosis fungoides and allogenic bone marrow transplantation Acta Derm Venereol 74 1994 331 332 (Pubitemid 24243864)
101. K. Kahata, S. Hashino, M. Takahata, F. Fujisawa, T. Kondo, S. Kobayashi, et al. Durable remission of Sézary syndrome after unrelated bone marrow transplantation by reduced-intensity conditioning Acta Haematol 120 2008 14 18
102. J.B. Yu, J.M. McNiff, M.W. Lund, and L.D. Wilson Treatment of primary cutaneous CD30+ anaplastic large-cell lymphoma with radiation therapy Int J Radiat Oncol Biol Phys 70 2008 1542 1545
103. M.W. Bekkenk, F.A. Geelen, P.C. van Voorst Vader, F. Heule, M.L. Geerts, and W.A. van Vloten Primary and secondary cutaneous CD30(+) lymphoproliferative disorders: a report from the Dutch Cutaneous Lymphoma Group on the long-term follow-up data of 219 patients and guidelines for diagnosis and treatment Blood 95 2000 3653 3661 (Pubitemid 30412833)
104. E.C. Vonderheid, A. Sajjadian, and M.E. Kadin Methotrexate is effective therapy for lymphomatoid papulosis and other primary cutaneous CD30-positive lymphoproliferative disorders J Am Acad Dermatol 34 1996 470 481 (Pubitemid 26083827)
105. M. Rodrigues, C. McCormack, L.M. Yap, H.M. Prince, H. Roberts, R. Williams, et al. Successful treatment of lymphomatoid papulosis with photodynamic therapy Australas J Dermatol 50 2009 129 132
106. A.F. Wahl, K. Klussman, J.D. Thompson, J.H. Chen, L.V. Francisco, and G. Risdon The anti-CD30 monoclonal antibody SGN-30 promotes growth arrest and DNA fragmentation in vitro and affects antitumor activity in models of Hodgkin's disease Cancer Res 62 2002 3736 3742 (Pubitemid 34728855)
107. Forero-Torres A, Leonard JP, Younes A, Rosenblatt JD, Brice P, Bartlett NL, et al. A Phase II study of SGN-30 (anti-CD30 mAb) in Hodgkin lymphoma or systemic anaplastic large cell lymphoma. Br J Haematol. 2009 (In press).
108. M. Duvic, Y. Kim, S. Reddy, A. Forero-Torres, L.C. Pinter-Brown, M.U. Rarick, et al. Phase II preliminary results of SGN-30 (anti-CD30 mAb) in patients with CD30+ lymphoproliferative disorders Blood 108 Suppl 2006 2733
109. R. Piccinno, M. Caccialanza, E. Berti, and L. Baldini Radiotherapy of cutaneous B cell lymphomas: our experience in 31 cases Int J Radiat Oncol Biol Phys 27 1993 385 389 (Pubitemid 23304466)
110. R. Piccinno, M. Caccialanza, and E. Berti Dermatologic radiotherapy of primary cutaneous follicle center cell lymphoma Eur J Dermatol 13 2003 49 52 (Pubitemid 36228508)
111. N.J. Senff, J.J. Hoefnagel, K.J. Neelis, M.H. Vermeer, E.M. Noordijk, and R. Willemze Results of radiotherapy in 153 primary cutaneous B-Cell lymphomas classified according to the WHO-EORTC classification Arch Dermatol 143 2007 1520 1526 (Pubitemid 350277767)
112. N.J. Senff, E.M. Noordijk, Y.H. Kim, M. Bagot, E. Berti, L. Cerroni, et al. European Organization for Research and Treatment of Cancer and International Society for Cutaneous Lymphoma consensus recommendations for the management of cutaneous B-cell lymphomas Blood 112 2008 1600 1609
113. A. Cozzio, W. Kempf, R. Schmid-Meyer, M. Gilliet, S. Michaelis, and L. Schärer Intra-lesional low-dose interferon alpha2a therapy for primary cutaneous marginal zone B-cell lymphoma Leuk Lymphoma 47 2006 865 869 (Pubitemid 43840642)
114. B. Kütting, G. Bonsmann, D. Metze, T.A. Luger, and L. Cerroni Borrelia burgdorferi-associated primary cutaneous B cell lymphoma: complete clearing of skin lesions after antibiotic pulse therapy or intralesional injection of interferon alfa-2a J Am Acad Dermatol 36 1997 311 314 (Pubitemid 27078893)
115. A. Parodi, C. Micalizzi, and A. Rebora Intralesional natural interferon alpha in the treatment of Crosti's lymphoma (primary cutaneous B follicular centre-cell lymphoma): report of four cases J Dermatol Treatment 7 1996 105 107 (Pubitemid 26235534)
116. P. Rubegni, G. De Aloe, E. Pianigiani, S. Lazzi, and M. Fimiani Primary cutaneous B-cell lymphoma: treatment with low dose intralesional recombinant interferon-alpha 2A J Eur Acad Dermatol Venereol 12 1999 70 71 (Pubitemid 29132996)
117. T. Zenone, G. Catimel, N. Barbet, and M. Clavel Complete remission of a primary cutaneous B cell lymphoma treated with intralesional recombinant interferon alpha-2a Eur J Cancer 30 1994 246 247
118. M.R. Smith Rituximab (monoclonal anti-CD20 antibody): mechanisms of action and resistance Oncogene 22 2003 7359 7368
119. E. Kimby Tolerability and safety of rituximab (MabThera) Cancer Treat Rev 31 2005 456 473
120. A.V. Morales, R. Advani, S.M. Horwitz, N. Riaz, S. Reddy, R.T. Hoppe, et al. Indolent primary cutaneous B-cell lymphoma: experience using systemic rituximab J Am Acad Dermatol 59 2008 953 957
121. S. Gellrich, J.M. Muche, A. Wilks, K.C. Jasch, C. Voit, and T. Fischer Systemic eight-cycle anti-CD20 monoclonal antibody (rituximab) therapy in primary cutaneous B-cell lymphomas-an applicational observation Br J Dermatol 153 2005 167 173 (Pubitemid 41044544)
122. L. Heinzerling, R. Dummer, W. Kempf, M.H. Schmid, and G. Burg Intralesional therapy with anti-CD20 monoclonal antibody rituximab in primary cutaneous B-cell lymphoma Arch Dermatol 136 2000 374 378 (Pubitemid 30149111)
123. K. Kerl, C. Prins, J.H. Saurat, and L.E. French Intralesional and intravenous treatment of cutaneous B-cell lymphomas with the monoclonal anti-CD20 antibody rituximab: report and follow-up of eight cases Br J Dermatol 155 2006 1197 1200 (Pubitemid 44729995)
124. F. Grange, M. Beylot-Barry, P. Courville, E. Maubec, M. Bagot, and B. Vergier Primary cutaneous diffuse large B-cell lymphoma, leg type: clinicopathologic features and prognostic analysis in 60 cases Arch Dermatol 143 2007 1144 1150 (Pubitemid 47443366)
125. N. Mounier, J. Briere, C. Gisselbrecht, J.F. Emile, P. Lederlin, and C. Sebban Rituximab plus CHOP (R-CHOP) overcomes bcl-2-associated resistance to chemotherapy in elderly patients with diffuse large B-cell lymphoma (DLBCL) Blood 101 2003 4279 4284 (Pubitemid 36857789)
126. B. Coiffier, E. Lepage, J. Briere, R. Herbrecht, H. Tilly, and R. Bouabdallah CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma N Engl J Med 346 2002 235 242 (Pubitemid 34438862)
127. P. Feugier, A. Van Hoof, C. Sebban, P. Solal-Celigny, R. Bouabdallah, and C. Fermé Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: a study by the Groupe d'Étude des Lymphomes de l'Adulte J Clin Oncol 23 2005 4117 4126 (Pubitemid 46211317)
128. C. Nourigat, C.C. Badger, and I.D. Bernstein Treatment of lymphoma with radiolabeled antibody: elimination of tumor cells lacking target antigen J Natl Cancer Inst 82 1990 47 50 (Pubitemid 20020893)
129. S. Maza, S. Gellrich, C. Assaf, M. Beyer, L. Spilker, H. Orawa, et al. Yttrium-90 ibritumomab tiuxetan radioimmunotherapy in primary cutaneous B-cell lymphomas: first results of a prospective, monocentre study Leuk Lymphoma 49 2008 1702 1709
130. R.L. Piekarz, R.W. Robey, Z. Zhan, G. Kayastha, A. Sayah, and A.H. Abdeldaim T-cell lymphoma as a model for the use of histone deacetylase inhibitors in cancer therapy: impact of depsipeptide on molecular markers, therapeutic targets, and mechanisms of resistance Blood 103 2004 4636 4643 (Pubitemid 38745996)
131. M.F. Demierre, S. Gan, J. Jones, and D.R. Miller Significant impact of cutaneous T-cell lymphoma on patients' quality of life Cancer 107 2006 2504 2511